Tetsunari Hase

16PUBLICATIONS
69CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsSocial epidemiologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Feb 02, 2026
Analysis of Peripheral T Cell Profiling and Plasma Proteomics in Advanced NSCLC Patients Treated With Atezolizumab.

Atsuto Mouri, Hiroshi Kagamu, Koji Tamada

|Jun 14, 2025
Safety and efficacy of retreatment with immune checkpoint inhibitors after severe immune-related adverse events.

Kazuyuki Mizuno, Takanori Ito, Tsunaki Sawada

|Feb 12, 2025
Coactivation of innate immune suppressive cells induces acquired resistance against combined TLR agonism and PD-1 blockade.

Hitomi Nishinakamura, Sayoko Shinya, Takuma Irie

|Jun 07, 2024
Synthetic retinoid-mediated preconditioning of cancer-associated fibroblasts and macrophages improves cancer response to immune checkpoint blockade.

Takayuki Owaki, Tadashi Iida, Yuki Miyai

|Mar 25, 2024
Durvalumab plus carboplatin-etoposide treatment in a patient with small-cell lung cancer on hemodialysis: a case report and literature review.

Futoshi Ushijima, Tetsunari Hase, Yuki Yamashita

|Aug 14, 2023
Lethal ventricular arrhythmia due to entrectinib-induced Brugada syndrome: a case report and literature review.

Keisuke Futamura, Tetsunari Hase, Akihito Tanaka

Pageof 3

Frequent Collaborators

3 joint publications

Shintaro Iwama

2 joint publications

Hiroyoshi Nishikawa

2 joint publications

Atsushi Enomoto

2 joint publications

Hiroshi Arima